AXIM Biotechnologies is a leader in industrial hemp
biosciences focusing on the research, development and production of
pharmaceutical, nutraceutical and cosmetic products, as well as alternative
sources of energy. The company is setting the green standard for cannabinoid
bioscience through the discovery and commercialization of new materials and
technologies that promote healthy living while respecting the environment. By
exploring innovative pharmaceutical delivery systems and active pharmaceutical
ingredients, the company is advancing the market for the treatment of
debilitating conditions such as Parkinson’s disease, Alzheimer’s disease, ADHD,
spasticity, pain, restless leg syndrome and Crohn’s disease.
“AXIM Biotech is providing health conscious and
environmentally conscious consumers with all-natural alternatives,” stated Dr.
George E. Anastassov, Chief Executive Officer of AXIM.
The company is in a strong strategic position to thrive as
the global market for cannabis related products continues to expand with
loosening regulatory restrictions and evolving consumer opinion. According to
the Pew Research Center, domestic support for cannabis legalization is rapidly
outpacing opposition. In 2015, a slim majority of 53 percent of survey
respondents voted in favor of outright legalization, marking the first time
that a majority of Americans voted in this manner. Shifting opinions should
continue to drive demand for the company’s unique offerings moving forward.
In April, AXIM made global headlines following the
announcement of its line of Cannabigerol (CBG) products. Unlike other
cannabinoids, CBG is known to contain non-psychoactive cannabinoids and
essential amino acids that provide benefits to oral health. Included in this
revolutionary line are all-natural retail products such as toothpaste,
mouthwash, dentifrice, oral gel and lip balm. In May, the company secured an
exclusive license to develop and produce a cannabinoid-infused chewing gum,
expanding on AXIM’s product line.
“We feel that AXIM’s ability to research cannabinoids and
introduce unique delivery methods is a catalyst that will drive new demand for
both the consumer retail and pharmaceutical markets,” continued Anastassov.
In the coming months, AXIM will look to continue efforts
towards establishing itself as a world leader in the clinical development of
novel phytocannabinoid-based medicines and products. Through the demonstration
of clinical proof of concept in indications not met by current pharmacology,
the company should be in a strong strategic position to realize rapid growth in
the maturing global market.
For more information, visit www.aximbiotech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment